Regulatory compliance – Page 44

Inadequate worst-case selection during lifecycle management – risk-based validation alignment

Effective Strategies for Addressing Inadequate Worst-Case Selection in Lifecycle Management In pharmaceutical manufacturing, the importance of thorough validation during lifecycle management cannot be overstated. Inadequate worst-case selection can lead to…

ERES controls not implemented during system upgrade – preventing repeat Part 11 findings

Addressing ERES Control Failures During System Upgrades to Prevent Part 11 Noncompliance In an environment where regulatory compliance is paramount, the implementation of ERES controls plays a critical role, especially…

CSV compliance weak during change control – CAPA and revalidation strategy

Addressing Weaknesses in CSV Compliance During Change Control: A Practical Playbook Change control is an essential process in pharmaceutical manufacturing that ensures all modifications are documented, evaluated, and implemented without…

ERES controls not implemented during inspection walkthrough – inspection evidence requirements

Addressing ERES Control Issues During Inspection Walkthroughs In the realm of pharmaceutical manufacturing and quality control, the implementation of Electronic Records and Electronic Signatures (ERES) controls is critical. This is…

Incomplete validation lifecycle during site expansion – regulatory deficiency risk

Managing the Risks of Incomplete Validation Lifecycles During Pharmaceutical Site Expansion The pharmaceutical industry is under constant pressure to expand operations, which often leads to the complexities associated with incomplete…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – preventing repeat Part 11 findings

Managing Hybrid Paper-Electronic Workflow Risks During Inspections The increasing reliance on hybrid paper-electronic workflows in pharmaceutical manufacturing can lead to control issues, particularly during regulatory inspections. This article presents a…

Validation gaps identified during lifecycle management – preventing repeat validation findings

Addressing Validation Fails Throughout the Lifecycle Management Process Validation gaps can pose significant challenges in pharmaceutical manufacturing and quality assurance, particularly during lifecycle management. Professionals in production, QC, QA, engineering,…

System access controls weak during system upgrade – risk-based ERES remediation

Addressing Weak System Access Controls During the System Upgrade: A Comprehensive Playbook In today’s pharmaceutical landscape, ensuring robust system access controls is paramount, especially during system upgrades. Weaknesses in these…

Management review ineffective during inspection readiness – QMS maturity gap analysis

“`html Addressing Ineffective Management Reviews During Inspection Readiness: A QMS Playbook In the dynamic environment of pharmaceutical manufacturing, it is critical that management reviews are both effective and efficient, particularly…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – CAPA and revalidation strategy

Addressing Uncontrolled Hybrid Paper-Electronic Workflows During Inspection Walkthroughs In recent regulatory inspections, hybrid paper-electronic workflows have become a significant area of scrutiny. When not managed correctly, these workflows can lead…

Poor QMS metrics during management review – building an inspection-resilient QMS

Tackling Poor QMS Metrics During Management Review: A Playbook for an Inspection-Resilient System Pharmaceutical organizations often face the challenge of poor quality management system (QMS) metrics during internal management reviews.…

Record retention failures during inspection walkthrough – 21 CFR Part 11 compliance gaps

Managing Record Retention Challenges During FDA/EMA/MHRA Inspections In today’s regulatory landscape, adherence to record retention requirements is non-negotiable, particularly under 21 CFR Part 11. Failures in maintaining accurate records can…